Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
The oral CGRP* receptor antagonist ubrogepant significantly reduced headache pain and bothersome migraine-associated symptom of a single-attack, acute migraine, according to the ACHIEVE** I study presented at AAN 2018.
High intake of fish enriched with omega-3 polyunsaturated fatty acids (PUFAs) combined with fish oil supplements were associated with a lower risk of developing multiple sclerosis (MS), according to the MS Sunshine Study presented at the AAN 2018 Annual Meeting.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.